drugset
drugset / Trial / NCT05959109

A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants

NCT05959109 ↗

Phase 1 Completed 57 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to look at the amount of the study drug, peresolimab, that gets into the blood stream and how long it takes the body to get rid of it when given under the skin using test formulations versus reference formulation in healthy participants. The study will also evaluate the safety and tolerability of peresolimab and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately up to 17 weeks, including screening.

Timeline

Start
2023-07-21
Primary completion
2024-01-11
Completion
2024-01-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Peresolimab Monoclonal antibody — Subcutaneous

Indications

No indication recorded.